<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04210375</url>
  </required_header>
  <id_info>
    <org_study_id>JK07.1.01</org_study_id>
    <nct_id>NCT04210375</nct_id>
  </id_info>
  <brief_title>Study of JK07 in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF)</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-controlled, Single-ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of JK07 in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Salubris Biotherapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Salubris Biotherapeutics Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, randomized, double-blind, placebo-controlled, single-ascending dose study&#xD;
      to assess the safety, tolerability, immunogenicity, PK, and exploratory efficacy of JK07 in&#xD;
      subjects 18 to 80 years of age with HFrEF ≤40%.&#xD;
&#xD;
      Initially 5 cohorts are planned with the option to expand the study to a total of 7 cohorts.&#xD;
      The size of the cohorts will range from 5 to 9 subjects. Each cohort will include one single&#xD;
      active unblinded sentinel subject receiving a single IV dose of JK07 prior to randomized&#xD;
      single dose administration of JK07 or placebo [3:1] in the remainder of the cohort.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, randomized, double-blind, placebo-controlled, single-ascending dose study&#xD;
      to assess the safety, tolerability, immunogenicity, PK, and exploratory efficacy of JK07 in&#xD;
      HF subjects 18 to 80 years of age with LVEF ≤40%. Subjects must have been maintained on an&#xD;
      optimal HF medical regimen for at least 3 months prior to enrollment and remain on the same&#xD;
      treatment regimen throughout the course of the study, per the 2017 ACC/AHA/HFSA) treatment&#xD;
      guidelines.&#xD;
&#xD;
      At screening, eligible subjects will undergo a physical examination, 2-dimensional&#xD;
      transthoracic echocardiography (2D-TTE), ECG assessment, blood sampling for laboratory&#xD;
      parameters, and urine testing. Safety assessments at screening will include hematology,&#xD;
      biochemistry, coagulation, liver, and thyroid function.&#xD;
&#xD;
      Subjects will be observed in the hospital on continuous telemetry from the time of hospital&#xD;
      admission until shortly before discharge approximately 48 hours later. During this time, they&#xD;
      will additionally have safety labs, vital signs, PK and biomarker samples collected, and ECGs&#xD;
      and 2D-TTEs performed.&#xD;
&#xD;
      Only a single dose of the investigational product will be administered and only a single&#xD;
      hospital admission is planned per subject during the study. Subjects will complete follow-up&#xD;
      visits through 180 days after administration of the investigational product.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 21, 2020</start_date>
  <completion_date type="Anticipated">March 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-blind, placebo-controlled, single-ascending dose with single active sentinel subject per cohort</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of treatment-emergent adverse events [safety and tolerability]</measure>
    <time_frame>Screening to 30 days</time_frame>
    <description>All safety information will be collected and evaluated</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (area under the concentration versus time curve) of JK07</measure>
    <time_frame>Baseline to 60 days</time_frame>
    <description>Blood samples will be taken on Days 1-4, and Days 7, 11, 15, 22, 30, and 60</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Left ventricular and systemic vascular resistance assessment</measure>
    <time_frame>Screening to 180 days</time_frame>
    <description>2D-transthoracic echocardiography</description>
  </other_outcome>
  <other_outcome>
    <measure>Biomarkers</measure>
    <time_frame>Screening to 180 days</time_frame>
    <description>Assessment of potential predictive biomarkers</description>
  </other_outcome>
  <other_outcome>
    <measure>Concentration-QT correlation</measure>
    <time_frame>Baseline to Day 3</time_frame>
    <description>Assess the possible relationship between JK07 plasma concentrations and any observed change in QT intervals</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">63</enrollment>
  <condition>Heart Failure With Reduced Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>JK07</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose of JK07 administered by intravenous infusion over 60 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of placebo administered by intravenous infusion over 60 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JK07</intervention_name>
    <description>Recombinant fusion protein consisting of a fully human immunoglobulin G1 monoclonal antibody and an active polypeptide fragment of the human growth factor NRG-1</description>
    <arm_group_label>JK07</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <description>Vehicle control</description>
    <arm_group_label>Matching Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults 18 and 80 years with stable NYHA Class II or III HF diagnosis (ischemic or&#xD;
             non-ischemic confirmed by medical history) at least 6 months prior to enrollment as&#xD;
             confirmed by medical history.&#xD;
&#xD;
          2. Stable HF defined as no hospitalizations for cardiac-related issues within the&#xD;
             previous 3 months prior to the screening visit or between screening and randomization,&#xD;
             other than for routine device generator changes.&#xD;
&#xD;
          3. Subjects with clearly interpretable echocardiographic images and with a screening LVEF&#xD;
             ≤ 40% in the absence of ≥ Grade 3 valvular disease on 2D-TTE.&#xD;
&#xD;
          4. Subjects must be taking clinician-directed appropriate pharmacological therapy for HF&#xD;
             as per the 2017 ACC/AHA/HFSA treatment guidelines at stable doses (except for&#xD;
             diuretics) for at least 3 months prior to screening. Subjects with implantable&#xD;
             cardioverter-defibrillators (ICDs), if the devices are not &quot;pacing&quot;, are eligible.&#xD;
&#xD;
          5. Body mass index ≥18 kg/m2 and ≤40 kg/m2.&#xD;
&#xD;
          6. Screening hemoglobin ≥9.0 g/dL, platelets ≥100 K/mL, ANC ≥1500/mL.&#xD;
&#xD;
          7. Able and willing to use adequate contraception until the end of the study.&#xD;
&#xD;
          8. Capable of providing informed consent and to comply with the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participating in any other study, have received any other investigational drug within&#xD;
             30 days prior to screening or 5-half-lives or any other investigational implanted&#xD;
             device within 30 days prior to screening, or are taking part in a nonmedication study&#xD;
             which, in the opinion of the Investigator, would interfere with study compliance or&#xD;
             outcome assessments.&#xD;
&#xD;
          2. Any past participation in a study that has investigated the NRG-1 pathway (e.g.,&#xD;
             Neucardin, Cimaglermin).&#xD;
&#xD;
          3. Heart failure due to hypertrophic cardiomyopathy, restrictive cardiomyopathy,&#xD;
             arrhythmogenic right ventricula dysplasia (ARVD), stress-induced (&quot;Takotsubo&quot;)&#xD;
             cardiomyopathy, chemotherapy-induced cardiomyopathy, peripartum cardiomyopathy,&#xD;
             infiltrative or inflammatory cardiomyopathies, and primary valvular disease.&#xD;
&#xD;
          4. Acute coronary syndrome within 3 months of screening or acute MI within 6 months of&#xD;
             screening.&#xD;
&#xD;
          5. Cardiac surgery, coronary artery revascularization, percutaneous coronary&#xD;
             intervention, or valvuloplasty within 3 months prior to screening.&#xD;
&#xD;
          6. Any subject who has received an indication for coronary revascularization within 3&#xD;
             months prior to screening.&#xD;
&#xD;
          7. Any major surgical procedure within 1 month prior to screening or planned surgical&#xD;
             procedure during the study period.&#xD;
&#xD;
          8. Sustained systolic blood pressure &lt;100 mm Hg and/or diastolic blood pressure &lt;50 mm&#xD;
             Hg.&#xD;
&#xD;
          9. Sustained resting heart rate &gt;100 beats per minute.&#xD;
&#xD;
         10. Cerebrovascular accident or hospitalizations for CV (cardiovascular) causes other than&#xD;
             routine device generator changes, including HF, chest pain, stroke, transient ischemic&#xD;
             attack, or arrhythmias within 3 months prior to randomization.&#xD;
&#xD;
         11. At screening have an abnormal or clinically significant 12-lead ECG abnormality, ei.;&#xD;
             (QRS &gt;120 msec, PR &gt;210 msec, heart rate (HR) &lt;45 bpm, sustained HR &gt;100 bpm) that, in&#xD;
             the opinion of the Investigator, would affect efficacy or safety evaluation or place&#xD;
             the subject at risk.&#xD;
&#xD;
         12. History or evidence of clinically significant arrhythmia uncontrolled by drug therapy&#xD;
             or use of an implantable defibrillator, long QT syndrome, or evidence of QT&#xD;
             prolongation with QTcF &gt;450 ms for males or QTcF &gt;470 ms for females prior to&#xD;
             randomization.&#xD;
&#xD;
         13. Clinically significant renal dysfunction as measured by the estimated GFR &lt;45&#xD;
             mL/min/1.73m2 at screening, or a clinically significant change in renal function&#xD;
             between screening and baseline.&#xD;
&#xD;
         14. Clinically significant liver dysfunction as measured by: ALT &gt;2.0 × ULN, alkaline&#xD;
             phosphatase &gt; 2.0 × ULN, AST &gt;2.0 × the ULN, or GGT &gt;2.0 × the ULN or serum bilirubin&#xD;
             ≥ 1.2 × the ULN at screening, or a clinically significant change in liver function&#xD;
             between screening and baseline.&#xD;
&#xD;
         15. Subjects with alteration of the coagulation panel (INR) and/or PT ≥ 1.5 × the ULN;&#xD;
             aPTT ≥ 1.5 × ULN, or serum albumin ≤ 3 gm/dL. For subjects on warfarin or other&#xD;
             anticoagulants, an INR (or PT/PTT) considered by the Principal Investigator as&#xD;
             therapeutically appropriate will be allowed.&#xD;
&#xD;
         16. Subjects with values of CPK and/or CK-MB &gt;2.5 times normal institutional limits at&#xD;
             screening.&#xD;
&#xD;
         17. Any subject who by Investigator's judgement, has a significant hematuria or&#xD;
             proteinuria at screening.&#xD;
&#xD;
         18. Concurrent treatment with Class I or III antiarrhythmic drugs (unless the medication&#xD;
             was discontinued more than 3 months before proposed enrollment).&#xD;
&#xD;
         19. Positive screening for HIV antibodies, hepatitis B surface antigen, or hepatitis C&#xD;
             virus antibodies.&#xD;
&#xD;
         20. Known history of or active alcohol abuse (no more than 14 units/week for males or 7&#xD;
             units/week for females) or use of illicit drugs within 1 year prior to randomization&#xD;
             other than recreational use of marijuana or cannabis-based products.&#xD;
&#xD;
         21. Other medical or psychiatric condition that, in the opinion of the Investigator, would&#xD;
             preclude obtaining voluntary consent/assent or would confound the secondary objectives&#xD;
             of study.&#xD;
&#xD;
         22. A history of malignancy of any type or any pre-malignant condition (e.g. ductal&#xD;
             carcinoma in situ, colonic polyp, or cervical atypia). All subjects are to undergo&#xD;
             cancer screening following study enrollment in accordance with American Cancer Society&#xD;
             Guidelines.&#xD;
&#xD;
         23. Pregnant or lactating female subjects at screening.&#xD;
&#xD;
         24. Subjects with clinically significant or poorly controlled disease including, but not&#xD;
             limited to, endocrine (including diabetes and thyroid) disease, neurological or&#xD;
             psychiatric (even mild), GI, hematological, urological, immunological, or ophthalmic&#xD;
             diseases as determined by the Investigator.&#xD;
&#xD;
         25. Subjects who are not non-smokers or light smokers (no more than 5 cigarettes per day)&#xD;
             and who cannot abstain from smoking from 2 weeks prior to the administration of IP&#xD;
             through the end of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wilson Tang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sam Murphy, PhD</last_name>
    <phone>617-584-3853</phone>
    <email>sam.murphy@salubrisbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Arizona College of Medicine</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724-5039</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nancy Sweitzer, MD, PhD</last_name>
      <phone>520-626-2000</phone>
    </contact>
    <contact_backup>
      <last_name>Lizzette Cruz</last_name>
      <phone>(520) 626-2471</phone>
      <email>marquez@shc.arizona.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Khadijah Breathett, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Friedman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elizabeth Juneman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Preethi William, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aaron Wolfson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandra Garcia, NP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sarah Salce, NP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Wheeler, MD, PhD</last_name>
      <phone>650-723-5468</phone>
    </contact>
    <contact_backup>
      <last_name>Jennifer Kim</last_name>
      <phone>(650) 725-6911</phone>
      <email>jennckim@stanford.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Matsataka Kawana, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karim Sallam, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harvard Medical School/ Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114-2696</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aferdita Spahillari, MD</last_name>
      <phone>617-643-6849</phone>
    </contact>
    <contact_backup>
      <last_name>Lizzie Suschana</last_name>
      <phone>(617) 726-2488</phone>
      <email>ESUSCHANA@mgh.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jennifer Ho, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Naylor, MD, MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wilson Tang, MD</last_name>
      <phone>216-444-6697</phone>
    </contact>
    <contact_backup>
      <last_name>Teresa Fonk</last_name>
      <phone>(216) 445-1766</phone>
      <email>fonkt@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jerry Estep, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>J Emanuel Finet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health Science University Hospital</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johannes Steiner, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>John Halvorson</last_name>
      <phone>(503) 418-1679</phone>
      <email>halvorsj@ohsu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kelly Graham, NP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephen Heitner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joyce W Wald, DO</last_name>
      <phone>215-615-0719</phone>
      <email>joyce.wald@uphs.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Nicole Escobar</last_name>
      <phone>(609) 519-8366</phone>
      <email>Nicole.Escobar@Pennmedicine.upenn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kenneth Margulies, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 17, 2019</study_first_submitted>
  <study_first_submitted_qc>December 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2019</study_first_posted>
  <last_update_submitted>February 13, 2021</last_update_submitted>
  <last_update_submitted_qc>February 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>heart failure</keyword>
  <keyword>HFrEF</keyword>
  <keyword>neuregulin 1</keyword>
  <keyword>NRG-1</keyword>
  <keyword>heregulin</keyword>
  <keyword>HER3</keyword>
  <keyword>HER4</keyword>
  <keyword>ErbB3</keyword>
  <keyword>ErbB4</keyword>
  <keyword>reduced ejection fraction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

